Eton Pharmaceuticals (ETON) Competitors $19.62 -0.21 (-1.06%) As of 11:28 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock ETON vs. DYN, HRMY, IMCR, APGE, SRPT, AUPH, CDTX, VCEL, PAHC, and ARDXShould you be buying Eton Pharmaceuticals stock or one of its competitors? The main competitors of Eton Pharmaceuticals include Dyne Therapeutics (DYN), Harmony Biosciences (HRMY), Immunocore (IMCR), Apogee Therapeutics (APGE), Sarepta Therapeutics (SRPT), Aurinia Pharmaceuticals (AUPH), Cidara Therapeutics (CDTX), Vericel (VCEL), Phibro Animal Health (PAHC), and Ardelyx (ARDX). These companies are all part of the "pharmaceutical products" industry. Eton Pharmaceuticals vs. Its Competitors Dyne Therapeutics Harmony Biosciences Immunocore Apogee Therapeutics Sarepta Therapeutics Aurinia Pharmaceuticals Cidara Therapeutics Vericel Phibro Animal Health Ardelyx Eton Pharmaceuticals (NASDAQ:ETON) and Dyne Therapeutics (NASDAQ:DYN) are both small-cap medical companies, but which is the better business? We will contrast the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, analyst recommendations, dividends, valuation and profitability. Which has more volatility & risk, ETON or DYN? Eton Pharmaceuticals has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Comparatively, Dyne Therapeutics has a beta of 1.1, suggesting that its share price is 10% more volatile than the S&P 500. Is ETON or DYN more profitable? Dyne Therapeutics has a net margin of 0.00% compared to Eton Pharmaceuticals' net margin of -7.10%. Eton Pharmaceuticals' return on equity of -0.73% beat Dyne Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Eton Pharmaceuticals-7.10% -0.73% -0.22% Dyne Therapeutics N/A -64.12%-56.75% Does the media prefer ETON or DYN? In the previous week, Eton Pharmaceuticals had 4 more articles in the media than Dyne Therapeutics. MarketBeat recorded 4 mentions for Eton Pharmaceuticals and 0 mentions for Dyne Therapeutics. Eton Pharmaceuticals' average media sentiment score of 0.22 beat Dyne Therapeutics' score of 0.00 indicating that Eton Pharmaceuticals is being referred to more favorably in the media. Company Overall Sentiment Eton Pharmaceuticals Neutral Dyne Therapeutics Neutral Do insiders & institutionals believe in ETON or DYN? 27.9% of Eton Pharmaceuticals shares are held by institutional investors. Comparatively, 96.7% of Dyne Therapeutics shares are held by institutional investors. 14.9% of Eton Pharmaceuticals shares are held by insiders. Comparatively, 20.8% of Dyne Therapeutics shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Which has higher earnings & valuation, ETON or DYN? Eton Pharmaceuticals has higher revenue and earnings than Dyne Therapeutics. Eton Pharmaceuticals is trading at a lower price-to-earnings ratio than Dyne Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEton Pharmaceuticals$39.01M13.49-$3.82M-$0.16-122.63Dyne TherapeuticsN/AN/A-$317.42M-$3.86-3.43 Do analysts prefer ETON or DYN? Eton Pharmaceuticals presently has a consensus price target of $29.67, indicating a potential upside of 51.21%. Dyne Therapeutics has a consensus price target of $34.07, indicating a potential upside of 157.59%. Given Dyne Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dyne Therapeutics is more favorable than Eton Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Eton Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 3.00Dyne Therapeutics 0 Sell rating(s) 2 Hold rating(s) 11 Buy rating(s) 3 Strong Buy rating(s) 3.06 SummaryDyne Therapeutics beats Eton Pharmaceuticals on 8 of the 15 factors compared between the two stocks. Get Eton Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for ETON and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding ETON and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart ETON vs. The Competition Export to ExcelMetricEton PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$528.84M$3.13B$5.72B$10.40BDividend YieldN/A2.36%5.53%4.58%P/E Ratio-123.2421.0076.4326.62Price / Sales13.49255.87472.7192.34Price / CashN/A46.3537.4661.85Price / Book20.879.8013.276.45Net Income-$3.82M-$52.73M$3.29B$271.39M7 Day Performance10.97%4.70%2.60%3.06%1 Month Performance13.41%6.23%4.65%7.62%1 Year Performance241.22%18.77%74.34%30.20% Eton Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)ETONEton Pharmaceuticals1.8741 of 5 stars$19.62-1.1%$29.67+51.2%+240.1%$528.84M$39.01M-123.2420Positive NewsDYNDyne Therapeutics3.3464 of 5 stars$12.86-2.2%$34.07+164.9%-61.9%$1.87BN/A-3.33100HRMYHarmony Biosciences4.5372 of 5 stars$32.50+0.3%$51.00+56.9%-16.2%$1.86B$714.73M10.48200Positive NewsGap DownIMCRImmunocore1.9471 of 5 stars$34.42-2.3%$56.89+65.3%+11.8%$1.78B$310.20M-86.05320APGEApogee Therapeutics2.229 of 5 stars$36.86-0.1%$97.29+163.9%-33.9%$1.70BN/A-8.9291Positive NewsSRPTSarepta Therapeutics4.3462 of 5 stars$17.47+0.5%$39.32+125.1%-85.6%$1.70B$1.90B-20.081,372Analyst UpgradeAUPHAurinia Pharmaceuticals2.7352 of 5 stars$12.81+0.5%$12.00-6.3%+86.2%$1.68B$235.13M29.79300CDTXCidara Therapeutics3.3257 of 5 stars$66.91+2.0%$64.14-4.1%+576.1%$1.66B$1.27M-6.0190News CoverageAnalyst ForecastGap UpHigh Trading VolumeVCELVericel2.8622 of 5 stars$31.42-2.4%$60.40+92.2%-32.7%$1.62B$237.22M261.86300PAHCPhibro Animal Health4.4611 of 5 stars$39.53-0.2%$28.40-28.2%+74.7%$1.61B$1.30B33.502,475Positive NewsInsider TradeARDXArdelyx4.2652 of 5 stars$6.53-1.2%$11.70+79.2%+3.9%$1.59B$333.61M-28.3990 Related Companies and Tools Related Companies DYN Alternatives HRMY Alternatives IMCR Alternatives APGE Alternatives SRPT Alternatives AUPH Alternatives CDTX Alternatives VCEL Alternatives PAHC Alternatives ARDX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:ETON) was last updated on 9/24/2025 by MarketBeat.com Staff From Our PartnersWhat The Silver Boom Could Mean For You…AI, electric vehicles, and even global central banks are quietly fueling record demand for silver. This once-o...Goldco Precious Metals | SponsoredWhy More Investors Are Using Family Trusts to Protect Their WealthFor many investors, a family trust can be an essential tool for protecting assets, avoiding probate, and ensur...SmartAsset | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWarren Buffett’s #1 AI Stock: Not Mag 7, And NOT on the NasdaqNew Amazon Crisis Could Tank U.S. Stock Market A new panic is halting AI projects at Amazon and could split...Altimetry | SponsoredIRS Wants Another Check on Sept 15th—What If You Could Keep It Instead?On September 15th, the IRS collects another round of quarterly tax payments—targeting self-employed profession...American Alternative | SponsoredBuffett, Gates and Bezos Quietly Dumping Stocks—Here's WhyImagine a bull market so powerful, every single investor became a millionaire. Not by finding the next NVIDIA ...Banyan Hill Publishing | SponsoredRecession Risk: 90% — Are Your Savings Ready?Moody's latest report shows one-third of U.S. economic activity is already in recession or at high risk.Lear Capital | SponsoredThis is the “End of Tesla” as we know it…Jeff has identified five of the past seven number-one performing tech stocks — before they took off. His Tesla...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Eton Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Eton Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free ETON Stock Alerts